The Science & Treatment of Obsessive-Compulsive Disorder (OCD)
Huberman Lab Podcast Recap
Published:
Duration: 3 hr 26 min
Guests: Dr. Helen Blair Simpson, Christopher Pittenger, Matthew Johnson, Blair Simpson, Nolan Williams, Paul Conti, Dr. Blair Simpson
Summary
This episode provides an in-depth look at Obsessive Compulsive Disorder (OCD), its debilitating impact, and the various treatment options available including cognitive behavioral therapy and pharmacotherapy. Key insights include the importance of the sequence of treatment application and the role...
What Happened
Andrew Huberman, a professor of neurobiology and ophthalmology at Stanford, explains that OCD is the seventh most debilitating illness worldwide, affecting 2.5% to 4% of the population. He distinguishes OCD from Obsessive Compulsive Personality Disorder, noting the former's intrusive obsessions and compulsions bound by anxiety.
Effective treatments for OCD include cognitive behavioral therapy (CBT), SSRIs, and transcranial magnetic stimulation (TMS). Huberman emphasizes that the sequence in which therapies are applied is crucial for optimal treatment outcomes. SSRIs are noted for their ability to suppress activity in the corticostriatal-thalamic loop, a brain circuit involved in OCD.
The episode highlights the genetic component of OCD, with 40-50% of cases having some genetic basis. Huberman discusses the corticostriatal-thalamic loop's role in reinforcing obsessions and compulsions, and how CBT aims to disrupt this loop by increasing anxiety temporarily to prevent compulsions.
Dr. Helen Blair Simpson's research at Columbia University is mentioned, focusing on the effectiveness of exposure-based CBT. This approach involves both real and imaginal exposures to obsessions and compulsions and typically includes 15 exposure sessions over 12 weeks.
Huberman discusses alternative treatments being explored, such as psilocybin and ketamine, which target different neurotransmitter systems. Cannabis is noted to show little acute impact on OCD symptoms, while ketamine shows some promising, yet inconclusive, results.
Hormonal studies reveal that cortisol and DHEA levels are elevated in OCD patients, with cortisol being higher in both males and females, and testosterone reduced in males. Such findings suggest hormonal treatments could potentially aid in managing OCD symptoms.
The episode concludes with a discussion on the importance of understanding neural mechanisms in OCD. This understanding can lead to more effective treatment strategies, including a combination of behavioral, pharmacological, and brain-machine interface therapies.
Key Insights
- OCD is characterized by intrusive obsessions and compulsions that are reinforced by anxiety, affecting up to 4% of the population globally. The disorder is distinct from Obsessive Compulsive Personality Disorder, which lacks these intrusive obsessions.
- The corticostriatal-thalamic loop in the brain is highly active in individuals with OCD, reinforcing compulsive behaviors. Both SSRIs and CBT have been shown to reduce activity in this loop, with significant symptom reduction typically appearing by 10 to 12 weeks.
- Research indicates a genetic component in OCD, with 40-50% of cases having a genetic basis. Hormonal studies suggest elevated cortisol and DHEA levels in OCD patients, indicating potential new avenues for treatment.
- Emerging treatments include psilocybin and ketamine, which target serotonin and glutamate systems respectively. While cannabis showed little acute impact on symptoms, ketamine presents some promising but inconclusive results.